Huagongshe화공사 화학 정보 인쇄 보고서 · 연구 참고용

HCID 39765생성일: 2026년 11월 4일

Vecuronium

BGSZAXLLHYERSY-XQIGCQGXSA-N · 1-[(2β,3α,5α,16β,17β)-3,17-Bis(acetyloxy)-2-(1-piperidinyl)androstan-16-yl]-1-methylpiperidinium · Piperidinium, 1-[(2b,3a,5a,16b,17b)-3,17-bis(acetyloxy)-2-(1-piperidinyl)androstan-16-yl]-1-methyl- (9CI)

https://huagongshe.com/ko/chemical/39765

식별자 및 물리적 특성

CAS No.	50700-72-6
분자식	C34H57N2O4+
평균 분자량	557.8 g/mol
단동위원소 질량	557.4318333 g/mol
SMILES	CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C[C@H]([N+]3(C)CCCCC3)[C@@H]4OC(C)=O)[C@@]2(C)C[C@@H]1N1CCCCC1
InChIKey	BGSZAXLLHYERSY-XQIGCQGXSA-N
PubChem CID	39765
ChEMBL	CHEMBL1201219
ChEBI	CHEBI:9939
DTXSID	DTXSID1044146

화학 및 물리적 성질

XLogP	6.5
극성 표면적	55.8
수소 결합 공여자 수	0
수소 결합 수용자 수	5
회전 가능 결합 수	6
무거운 원자 수	40
형식 전하	1
복잡도	958
의약품	Pharmaceuticals -> Listed in ZINC15
용해도	1.86e-05 g/L
Human Drugs	Breast FeedingLactationMuscle RelaxantsNeuromuscular Nondepolarizing AgentsMuscle relaxants (peripherally-acting) and cholinesterase inhibitors
Physical Description	Solid
Collision Cross Section	246.83 Å² [M]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards]

안전 및 규제

유해 작용	The primary adverse event associated with all nondepolarizing neuromuscular agents is the extension of the drug's pharmacological effect past the needed time of use, resulting in adverse effects ranging from skeletal muscle weakness to extended muscular paralysis leading to respiratory insufficiency or apnea.
독성 요약	The risk of iatrogenic overdosage can be reduced by closely monitoring muscle twitch responses using peripheral nerve stimulation. Anticholinesterases antagonize neuromuscular blockade actiontherefore, acetylcholinesterase inhibitors such as neostigmine are useful to reverse rocuronium and vecuronium's effect on muscle paralysis.
Drug Induced Liver Injury	Drug-Induced Liver Injury Severity and Toxicity (DILIst)vecuroniumDILI NegativeIntravenousDOI:10.1016/j.drudis.2019.09.022
Effects During Pregnancy and Lactation	◉ Summary of Use during Lactation

식별자 및 물리적 특성

CAS No.

50700-72-6

분자식

C34H57N2O4+

평균 분자량

557.8 g/mol

단동위원소 질량

557.4318333 g/mol

SMILES

CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C[C@H]([N+]3(C)CCCCC3)[C@@H]4OC(C)=O)[C@@]2(C)C[C@@H]1N1CCCCC1

InChIKey

BGSZAXLLHYERSY-XQIGCQGXSA-N

PubChem CID

39765

ChEMBL

CHEMBL1201219

ChEBI

CHEBI:9939

DTXSID

DTXSID1044146

화학 및 물리적 성질

XLogP

6.5

극성 표면적

55.8

수소 결합 공여자 수

수소 결합 수용자 수

회전 가능 결합 수

무거운 원자 수

형식 전하

복잡도

958

의약품

Pharmaceuticals -> Listed in ZINC15

용해도

1.86e-05 g/L

Human Drugs

Breast FeedingLactationMuscle RelaxantsNeuromuscular Nondepolarizing AgentsMuscle relaxants (peripherally-acting) and cholinesterase inhibitors

Physical Description

Solid

Collision Cross Section

246.83 Å² [M]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards]

안전 및 규제

유해 작용

The primary adverse event associated with all nondepolarizing neuromuscular agents is the extension of the drug's pharmacological effect past the needed time of use, resulting in adverse effects ranging from skeletal muscle weakness to extended muscular paralysis leading to respiratory insufficiency or apnea.

독성 요약

The risk of iatrogenic overdosage can be reduced by closely monitoring muscle twitch responses using peripheral nerve stimulation. Anticholinesterases antagonize neuromuscular blockade actiontherefore, acetylcholinesterase inhibitors such as neostigmine are useful to reverse rocuronium and vecuronium's effect on muscle paralysis.

Drug Induced Liver Injury

Drug-Induced Liver Injury Severity and Toxicity (DILIst)vecuroniumDILI NegativeIntravenousDOI:10.1016/j.drudis.2019.09.022

Effects During Pregnancy and Lactation

◉ Summary of Use during Lactation